[1] XIE C,WAN X,QUAN H,et al. Preclinical characterization of anlotinib,a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor[J]. Cancer Sci,2018,109(4):1207-1219.
|
[2] HAN B,LI K,WANG Q,et al. Effect of Anlotinib as a thirdline or further treatment on overall survival of patients with advanced non-small cell lung cancer:The ALTER 0303 phase 3randomized clinical trial[J]. JAMA Oncol,2018,4(11):1569-1575.
|
[3] WANG G,SUN M,JIANG Y,et al. Anlotinib,a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma[J]. Int J Cancer,2019,145(4):979-993.
|
[4] SUN YK,DU F,GAO M. Anlotinib for the treatment of patients with locally advanced or metastatic medullary thyroid cancer[J]. Thyroid,2018,28(11):1455-1461.
|
[5] ZHONG CC,CHEN F,YANG JL,et al. Pharmacokinetics and disposition of anlotinib,an oral tyrosine kinase inhibitor,in experimental animal species[J]. Acta Pharmacol Sin,2018,39(6):1048-1063.
|
[6] YIN XY. Controversy and strategy of preoperative biliary drainage reducing jaundice in hilar cholangiocarcinoma[J]. Chin J Dig Surg,2018,17(3):229-232.(in Chinese)殷晓煜.肝门部胆管癌术前行胆道引流术减轻黄疸的争议与策略[J].中华消化外科杂志,2018,17(3):229-232.
|
[7] VALERO V,COSGROVE D,HERMAN JM,et al. Management of perihilar cholangiocareinoma in the era of multimodal therapy[J]. Expert Rev Gastroenterel Hepatol,2012,6(4):481-495.
|
[8] MURAKAMI Y,UEMURA K,SUDO T,et al. Perineural invasion in extrahepatic cholangiocarcinoma:Prognostic impact and treatment strategies[J]. J Gastrointest Surg,2013,17(8):1429-1439.
|
[9] CHEN XP,XIANG S. Therapy of hilar cholangiocarcinoma in the precise medicine period[J]. Chin J Dig Surg,2018,17(1):3-8.(in Chinese)陈孝平,项帅.精准医学时代肝门部胆管癌的治疗[J].中华消化外科杂志,2018,17(1):3-8.
|
[10] YANG B,XIE H,WANG CP,et al. Study on inhibition of arotinib on human intrahepatic cholangiocarcinoma cell line HCCC-9810[J]. Chin J Med Guide,2017,19(12):1389-1391.(in Chinese)杨斌,谢辉,王春平,等.安罗替尼对人肝内胆管细胞癌细胞系HCCC-9810作用研究[J].中国医药导刊,2017,19(12):1389-1391.
|
[11] ZHANG A,LIU B,XU D,et al. Advanced intrahepatic cholangiocarcinoma treated using anlotinib and microwave ablation:A case report[J]. Medicine(Baltimore),2019,98(52):e18435.
|